B Combe

Summary

Country: France

Publications

  1. ncbi request reprint Should patients with recent-onset polyarthritis receive aggressive treatment?
    Bernard Combe
    Immuno Rheumatology Department, Lapeyronie Teaching Hospital, 31, avenue du Doyen Gaston Giraud, 34295 Montpellier 5, France
    Joint Bone Spine 71:475-80. 2004
  2. pmc Rheumatoid arthritis and sexuality: a patient survey in France
    Gisela Kobelt
    Andar, Clermont l Hérault, France
    BMC Musculoskelet Disord 13:170. 2012
  3. pmc Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
    Bin Zhang
    Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA 02118, USA
    Arthritis Res Ther 14:R156. 2012
  4. ncbi request reprint [Indications and efficacy of biologics in inflammatory arthritis]
    Bernard Combe
    Rhumatologie, Hopital Lapeyronie, CHU de Montpellier Université Montpellier I, 371 avenue du Doyen Gaston Giraud 34295 Montpellier cedex 5
    Bull Acad Natl Med 196:1279-92; discussion 1293. 2012
  5. doi request reprint Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials
    Pierre LE Blay
    Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    J Rheumatol 39:712-5. 2012
  6. pmc Lymphotoxin α revisited: general features and implications in rheumatoid arthritis
    Flavia Calmon-Hamaty
    Institut de Génétique Moléculaire de Montpellier CNRS UMR 5535, 1919 Route de Mende, 34293 Montpellier, Cedex 5, France
    Arthritis Res Ther 13:232. 2011
  7. pmc Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
  8. pmc Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study
    Natacha Courvoisier
    Service de Rhumatologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris, 75012, France
    Arthritis Res Ther 10:R106. 2008
  9. pmc Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis
    Olivier Meyer
    Rheumatology Unit, Assistance Publique Hopitaux de Paris, Bichat University Hospital, 75018 Paris, France
    Arthritis Res Ther 8:R40. 2006
  10. pmc Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
    Antonio Naranjo
    Hospital de Gran Canaria Dr, Negrin, University of Las Palmas de Gran Canaria, Barranco de la Ballena s n 35011, Spain
    Arthritis Res Ther 10:R30. 2008

Collaborators

Detail Information

Publications75

  1. ncbi request reprint Should patients with recent-onset polyarthritis receive aggressive treatment?
    Bernard Combe
    Immuno Rheumatology Department, Lapeyronie Teaching Hospital, 31, avenue du Doyen Gaston Giraud, 34295 Montpellier 5, France
    Joint Bone Spine 71:475-80. 2004
    ..g., a combination of disease-modifying antirheumatic drugs or biological therapy) very early on with the goal of minimizing joint destruction and subsequent functional impairments...
  2. pmc Rheumatoid arthritis and sexuality: a patient survey in France
    Gisela Kobelt
    Andar, Clermont l Hérault, France
    BMC Musculoskelet Disord 13:170. 2012
    ..The objective of this study was to evaluate the impact of rheumatoid arthritis (RA) on patients' sexuality and identify disease and other factors such as fatigue that most influence sexual relationships...
  3. pmc Validation of ACR/EULAR definition of remission in rheumatoid arthritis from RA practice: the ESPOIR cohort
    Bin Zhang
    Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA 02118, USA
    Arthritis Res Ther 14:R156. 2012
    ..Validation of the RA remission criteria using observational study data is necessary before recommending their use in practice...
  4. ncbi request reprint [Indications and efficacy of biologics in inflammatory arthritis]
    Bernard Combe
    Rhumatologie, Hopital Lapeyronie, CHU de Montpellier Université Montpellier I, 371 avenue du Doyen Gaston Giraud 34295 Montpellier cedex 5
    Bull Acad Natl Med 196:1279-92; discussion 1293. 2012
    ..Current therapeutic strategies are based on disease activity and severity. International societies such as EULAR and ASAS have published precise recommendations for routine management of these patients...
  5. doi request reprint Short-term risk of total malignancy and nonmelanoma skin cancers with certolizumab and golimumab in patients with rheumatoid arthritis: metaanalysis of randomized controlled trials
    Pierre LE Blay
    Rheumatology Department, Lapeyronie Hospital, 371 Avenue du Doyen Gaston Giraud, 34295 Montpellier Cedex 5, France
    J Rheumatol 39:712-5. 2012
    ..To assess the risk of total malignancy and nonmelanoma skin cancers (NMSC) in patients with rheumatoid arthritis (RA) receiving certolizumab and golimumab through a metaanalysis of data from randomized control trials (RCT)...
  6. pmc Lymphotoxin α revisited: general features and implications in rheumatoid arthritis
    Flavia Calmon-Hamaty
    Institut de Génétique Moléculaire de Montpellier CNRS UMR 5535, 1919 Route de Mende, 34293 Montpellier, Cedex 5, France
    Arthritis Res Ther 13:232. 2011
    ..In this review, we aim to summarize the general features of LTα and what is currently known about its participation in RA...
  7. pmc Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: results from the RAPID 1 randomized controlled
    Vibeke Strand
    Division of Immunology Rheumatology, Stanford University School of Medicine, 306 Ramona Road, Palo Alto, CA, 94028, USA
    Arthritis Res Ther 11:R170. 2009
    ..The objective of this study was to assess the impact of certolizumab pegol (CZP) treatment on health-related quality of life (HRQoL), fatigue and other patient-reported outcomes (PROs) in patients with rheumatoid arthritis (RA)...
  8. pmc Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: a prospective study
    Natacha Courvoisier
    Service de Rhumatologie, Hopital Saint Antoine, 184 rue du Faubourg Saint Antoine, Paris, 75012, France
    Arthritis Res Ther 10:R106. 2008
    ..The objectives of this study were to determine the predictive factors of long-term radiographic outcome of rheumatoid arthritis (RA) and to describe the relationship between joint damage and disability over the course of the disease...
  9. pmc Serial determination of cyclic citrullinated peptide autoantibodies predicted five-year radiological outcomes in a prospective cohort of patients with early rheumatoid arthritis
    Olivier Meyer
    Rheumatology Unit, Assistance Publique Hopitaux de Paris, Bichat University Hospital, 75018 Paris, France
    Arthritis Res Ther 8:R40. 2006
    ..In conclusion, serially determined anti-CCP2 antibodies during the first three years of follow-up performs better than baseline determination for predicting radiographic progression in patients with early RA...
  10. pmc Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study
    Antonio Naranjo
    Hospital de Gran Canaria Dr, Negrin, University of Las Palmas de Gran Canaria, Barranco de la Ballena s n 35011, Spain
    Arthritis Res Ther 10:R30. 2008
    ....
  11. pmc Determining a low disease activity threshold for decision to maintain disease-modifying antirheumatic drug treatment unchanged in rheumatoid arthritis patients
    Michel De Bandt
    Centre hospitalier d Aulnay sous Bois, Service de Rhumatologie, Boulevard Ballanger, Aulnay sous Bois F 93600, France
    Arthritis Res Ther 11:R157. 2009
    ....
  12. pmc Apoptosis is not the major death mechanism induced by celecoxib on rheumatoid arthritis synovial fibroblasts
    Rachel Audo
    Institut de Genetique Moleculaire de Montpellier, 1919 Route de Mende, CNRS UMR5535, Montpellier, France
    Arthritis Res Ther 9:R128. 2007
    ..We therefore conclude that apoptosis is not the major death pathway in celecoxib-treated RA FLSs...
  13. ncbi request reprint The ESPOIR cohort: a ten-year follow-up of early arthritis in France: methodology and baseline characteristics of the 813 included patients
    Bernard Combe
    University Hospital, Montpellier, France
    Joint Bone Spine 74:440-5. 2007
    ....
  14. ncbi request reprint Early rheumatoid arthritis: strategies for prevention and management
    Bernard Combe
    Immuno Rhumatologie Hôpital Lapeyronie, CHU de Montpellier, University Montpellier I, 371, Avenue du Doyen Gaston Giraud 34295 Montpellier cedex 5, France
    Best Pract Res Clin Rheumatol 21:27-42. 2007
    ..Finally, the reduction or stopping of smoking, which could prevent the development and progression of early RA, is the only prevention tool currently available...
  15. doi request reprint Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study)
    Bernard Combe
    Service d Immuno Rhumatologie, Hopital Lapeyronie, Montpellier, France
    Rheumatology (Oxford) 48:425-32. 2009
    ..To compare cardiovascular (CV) and other safety and efficacy parameters of etoricoxib 60 and 90 mg, and diclofenac 150 mg...
  16. pmc EULAR recommendations for the management of early arthritis: report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT)
    B Combe
    Immuno Rhumatologie, Lapeyronie Hosp, Montpellier, France
    Ann Rheum Dis 66:34-45. 2007
    ..To formulate EULAR recommendations for the management of early arthritis...
  17. doi request reprint Predictors of radiographic progression in the ESPOIR cohort: the season of first symptoms may influence the short-term outcome in early arthritis
    G Mouterde
    Rheumatology Department, Montpellier 1 University, Lapeyronie Hospital, France
    Ann Rheum Dis 70:1251-6. 2011
    ..To determine predictors of short-term radiographic progression in an inception cohort of patients with early arthritis...
  18. ncbi request reprint Impact of dosing on treatment with TNF inhibitors: managing dose adjustment
    Bernard Combe
    Immuno Rhumatologie, Hopital Lapeyronie, Universite Montpellier I, France
    Clin Exp Rheumatol 28:S13-7. 2010
    ..At present, although dose adjustments are common, data are insufficient for consensus guidelines to be recommended...
  19. ncbi request reprint [Factors predictive of severity in rheumatoid arthritis]
    B Combe
    Federation de rhumatologie, CHU Lapeyronie, 34295 Montpellier Cedex 5, France
    Ann Med Interne (Paris) 152:522-6. 2001
    ..High ESR, CRP, positive rheumatoid factor with a high IgM (and IgA) titer, the presence of one of the HLA DRB1*04 alleles associated with RA, and early development of radiological lesions are all factors of prognosis...
  20. ncbi request reprint Predictive factors of 5-year health assessment questionnaire disability in early rheumatoid arthritis
    Bernard Combe
    Service d Immuno Rhumatologie, CHU Montpellier, INSERM U454, 34295 Montpellier Cedex 5, France
    J Rheumatol 30:2344-9. 2003
    ..To determine prognostic factors of disability in early rheumatoid arthritis (RA) and to investigate the radiological and functional course of the disease...
  21. doi request reprint Progression in early rheumatoid arthritis
    Bernard Combe
    Immuno Rhumatologie, Hopital Lapeyronie, CHU de Montpellier, Montpellier I University, Montpellier, France
    Best Pract Res Clin Rheumatol 23:59-69. 2009
    ..In addition, close monitoring of disease activity and radiographic progression is mandatory in order to adapt DMARD therapy and strategy if necessary...
  22. pmc Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study
    B Combe
    Service d Immuno Rhumatologie, Hopital Lapeyronie, Montpellier, France
    Ann Rheum Dis 68:1146-52. 2009
    ..To determine the efficacy and safety of etanercept and etanercept plus sulfasalazine versus sulfasalazine in patients with rheumatoid arthritis (RA) despite sulfasalazine therapy...
  23. doi request reprint Positivity for anti-cyclic citrullinated peptide is associated with a better response to abatacept: data from the 'Orencia and Rheumatoid Arthritis' registry
    J E Gottenberg
    Rhumatologie, Hopitaux Universitaires de Strasbourg, Centre de Référence National des Maladies Auto Immunes Systémique Rares, EA 4438 Physiopathologie des Arthrites, Strasbourg, France
    Ann Rheum Dis 71:1815-9. 2012
    ..Very limited data are available regarding the efficacy of abatacept (ABA) in real life. The aims of this study were to determine the efficacy of ABA in rheumatoid arthritis and predicting factors of efficacy in common practice...
  24. ncbi request reprint Factors determining a DMARD initiation in early inflammatory arthritis patients. The ESPOIR cohort study
    C Lukas
    Immuno Rhumatologie, Hopital Lapeyronie, Montpellier, France
    Clin Exp Rheumatol 27:84-91. 2009
    ..To describe the rate and timing of DMARD start in patients with early inflammatory arthritis in France, and to determine the factors leading to this treatment start...
  25. pmc Radiological damage in patients with rheumatoid arthritis on sustained remission
    G Cohen
    Immuno Rhumatologie, Montpellier I University, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
    Ann Rheum Dis 66:358-63. 2007
    ..To assess the radiological damage progression in patients with recent rheumatoid arthritis in sustained remission...
  26. pmc Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: a double-blind comparison
    B Combe
    Service d Immuno Rhumatologie, Hopital Lapeyronie, Montpellier, France
    Ann Rheum Dis 65:1357-62. 2006
    ..To compare the efficacy and safety of etanercept and sulfasalazine, alone and in combination, in patients with active rheumatoid arthritis despite sulfasalazine treatment...
  27. pmc HLA-DRB1 genes and patients with late onset rheumatoid arthritis
    J P Hellier
    , CHU Montpellier, France
    Ann Rheum Dis 60:531-3. 2001
    ..However, HLA-DRB1*04 RA linked alleles are not as closely associated with RA in the elderly as they are in younger patients. This suggests that the importance of these genes in the susceptibility to RA may be lower in elderly patients...
  28. pmc Anti-heat shock protein 70 kDa and 90 kDa antibodies in serum of patients with rheumatoid arthritis
    G Hayem
    Rheumatology Department, Bichat Teaching Hospital, Paris, France
    Ann Rheum Dis 58:291-6. 1999
    ....
  29. ncbi request reprint The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis
    G Cohen
    Service d Immuno Rhumatologie, Faculté de Médecine Montpellier I, Centre Hospitalier Universitaire Lapeyronie, Montpellier, France
    Clin Exp Rheumatol 23:795-800. 2005
    ..To determine whether it may be successful to try another TNF-alpha antagonist (infliximab or etanercept) when one has failed due to non response or the development of side effects...
  30. doi request reprint Favorable effect of very early disease-modifying antirheumatic drug treatment on radiographic progression in early inflammatory arthritis: Data from the Étude et Suivi des polyarthrites indifférenciées récentes (study and followup of early undifferentiate
    C Lukas
    Lapeyronie Hospital, Montpellier, France
    Arthritis Rheum 63:1804-11. 2011
    ..This study was undertaken to compare radiographic progression in patients treated with a DMARD very early in the course of their disease (within 3 months of diagnosis) and those who began DMARD treatment later...
  31. ncbi request reprint Comparison of intramuscular and oral meloxicam in rheumatoid arthritis patients
    B Combe
    , H pital Lapeyronie 371, Montpellier, France
    Inflamm Res 50:S10-6. 2001
    ..CONCLUSION: Oral and im meloxicam (15 mg) were both effective and well-tolerated for acute exacerbations of RA. The im formulation had some advantages, such as a faster onset of action...
  32. doi request reprint Serum levels of tumour necrosis factor family members a proliferation-inducing ligand (APRIL) and B lymphocyte stimulator (BLyS) are inversely correlated in systemic lupus erythematosus
    J Morel
    Service d Immuno Rhumatologie Université Montpellier, France
    Ann Rheum Dis 68:997-1002. 2009
    ..To determine whether serum levels of a proliferation-inducing ligand (APRIL) are altered in patients with systemic lupus erythematosus (SLE), and correlate with disease parameters...
  33. pmc HLA-DMA*0103 and HLA-DMB*0104 alleles as novel prognostic factors in rheumatoid arthritis
    J Morel
    Department of Immuno Rheumatology, Hospital Lapeyronie 34295, Montpellier Cedex 5, France
    Ann Rheum Dis 63:1581-6. 2004
    ..To evaluate HLA-DM alleles as markers for disease severity in rheumatoid arthritis (RA)...
  34. ncbi request reprint Characteristics and survival of 26 patients with paraneoplastic arthritis
    J Morel
    Department of Immuno Rheumatology, Montpellier I University and Lapeyronie Teaching Hospital, 34295 Montpellier, Cedex 5 France
    Ann Rheum Dis 67:244-7. 2008
    ..To date, only a few series of patients with paraneoplastic arthritis have been published. The charts of patients with cancer-associated arthritis were collected in order to describe characteristics of this rheumatism...
  35. ncbi request reprint [Rheumatoid arthritis]
    Jacques Morel
    Service d Immuno Rhumatologie, Centre Hospitalier Universitaire Lapeyronie, Montpellier
    Rev Prat 56:553-62. 2006
  36. doi request reprint Rheumatoid arthritis of the hand: monitoring with a simplified MR imaging scoring method--preliminary assessment
    Catherine Cyteval
    Department of Medical Imaging and Rheumatology, Hopital Lapeyronie, Montpellier Cedex 5, France
    Radiology 256:863-9. 2010
    ....
  37. ncbi request reprint Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces rheumatoid arthritis synovial fibroblast proliferation through mitogen-activated protein kinases and phosphatidylinositol 3-kinase/Akt
    Jacques Morel
    INSERM Unit 454, Centre Hospitalier Universitaire Arnaud de Villeneuve, Centre Hospitalier Universitaire Lapeyronie, 34295 Montpellier, France
    J Biol Chem 280:15709-18. 2005
    ..This dual functionality of TRAIL in stimulating apoptosis and proliferation has important implications for its use in the treatment of RA...
  38. ncbi request reprint Polymorphism of HLA-DMA and DMB alleles in patients with systemic lupus erythematosus
    Jacques Morel
    Service d Immunorhumatologie, Hopital Lapeyronie, Montpellier, France
    J Rheumatol 30:1485-90. 2003
    ..To evaluate the contribution of HLA-DM alleles to susceptibility to systemic lupus erythematosus (SLE) in a Caucasian population...
  39. ncbi request reprint The French early arthritis registry
    B Combe
    Service d Immuno Rhumatologie, Hopital Lapeyronie, 34295 Montpellier, France
    Clin Exp Rheumatol 21:S123-8. 2003
    ..The objectives, design and organization of this early arthritis registry are described...
  40. pmc HLA-DRB1 gene transcripts in rheumatoid arthritis
    S Kerlan-Candon
    Laboratoire d Immunologie, Centre Hospitalo Universitaire de Montpellier and Fédération de Rhumatologie, Centre Hospitalo Universitaire de Montpellier, Montpellier, France
    Clin Exp Immunol 124:142-9. 2001
    ..This particular regulation of DRB1 gene expression in RA patients could therefore represent one of the molecular mechanisms involved in the association of HLA DRB1 genes to RA...
  41. ncbi request reprint [Rheumatoid polyarthritis: therapeutic management]
    B Combe
    Federation de rhumatologie, Hopital Lapeyronie, CHU de Montpellier
    Presse Med 27:2070-4. 1998
    ..LONG-STANDING DISEASE: The precise therapeutic strategy in patients with long-standing disease remains a question of debate, but does require full-dose combination regimens...
  42. doi request reprint Tumor necrosis factor-alpha blockers in SAPHO syndrome
    Kaouther Ben Abdelghani
    Department of Immuno Rheumatology, Lapeyronie Hospital, Montpellier, Strasbourg, France
    J Rheumatol 37:1699-704. 2010
    ....
  43. doi request reprint The pleiotropic effect of TRAIL on tumor-like synovial fibroblasts from rheumatoid arthritis patients is mediated by caspases
    R Audo
    Institut de Genetique Moleculaire de Montpellier, CNRS UMR5535, Montpellier, France
    Cell Death Differ 16:1227-37. 2009
    ..The finding that TRAIL-triggered proliferation and apoptosis share intracellular routes has to be taken in consideration in defining therapeutic strategies on the basis of the administration of TRAIL...
  44. doi request reprint [Clostridium difficile associated reactive arthritis]
    K Ben Abdelghani
    Service d Immuno Rhumatologie, CHU Lapeyronie, Montpellier, France kawther
    Rev Med Interne 31:e13-5. 2010
    ..difficile enterocolitis. Samples obtained from urine and blood cultures remained sterile. Corticosteroids were prescribed and clinical manifestations resolved within 3 weeks. Ten months later, there was no relapse and no sequela...
  45. doi request reprint Sarcoid-like granulomatosis in patients treated with tumor necrosis factor blockers: 10 cases
    Claire Immediato Daïen
    CHU Lapeyronie, Service d Immuno Rhumatologie, Montpellier, France
    Rheumatology (Oxford) 48:883-6. 2009
    ..However, several cases of sarcoidosis have been diagnosed during anti-TNF therapy. Here, we report the largest series of sarcoid-like granulomatosis following TNF blocker treatment...
  46. ncbi request reprint Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis
    Jean David Cohen
    Department of Immuno Rhumatologie, CHU Montpellier, Montpellier I University and INSERM U454, Montpellier, France
    J Rheumatol 33:1936-41. 2006
    ..To evaluate and determine prognostic factors of 5-year quality of life in patients with early rheumatoid arthritis (RA)...
  47. ncbi request reprint Bone mineral density of 704 amateur sportsmen involved in different physical activities
    J Morel
    , Montpellier, France
    Osteoporos Int 12:152-7. 2001
    ..Head ratio is closely related to the type of practice; its value could predict whether sport participants have developed the maximal peak bone mass they could achieve...
  48. ncbi request reprint Thalidomide: new indications?
    B Combe
    Rheumatology Federation, Hopital Lapeyronie, Montpellier, France
    Joint Bone Spine 68:582-7. 2001
    ..This possibility requires further evaluation...
  49. doi request reprint Registries in rheumatoid arthritis and autoimmune diseases: data from the French registries
    Xavier Mariette
    Rheumatology Department, Hopital Lapeyronie, University Paris Sud 11 V, INSERM U1012, 371 Avenue du Doyen G Giraud, 34295 Montpellier Cedex 5, France
    Rheumatology (Oxford) 50:222-9. 2011
    ..Clinical registries have shown their effectiveness in capturing the long-term benefit of drugs in routine care. In France, two types of registry have been established to analyse the safety and efficacy of biological agents...
  50. doi request reprint Comparison of certolizumab pegol with other anticytokine agents for treatment of rheumatoid arthritis: a multiple-treatment Bayesian metaanalysis
    Robert Launois
    Departement de Rhumatologie, Hopital Lapeyronie, 371 Avenue du Doyen G Giraud, Montpellier Cedex 5, France
    J Rheumatol 38:835-45. 2011
    ....
  51. ncbi request reprint [What treatments can reduce the digestive complications of NSAIDs]
    Bernard Combe
    Service d Immunorhumatologie, Hopital Lapeyronie, Montpellier
    Presse Med 32:S33-7. 2003
    ..The aim is to compile a systematic review of literature data on the efficacy of GI protective agents in the prevention of upper GI lesions in a subject receiving long-term therapy with an NSAID...
  52. ncbi request reprint Recommendations of the French Society for Rheumatology. TNFalpha antagonist therapy in rheumatoid arthritis
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, UFR de Medecine, Universite Pierre et Marie Curie Paris VI, 83, Boulevard de l Hopital, 75651 Paris Cedex 13, France
    Joint Bone Spine 73:433-41. 2006
    ..To develop recommendations for TNFalpha-antagonist therapy in patients with rheumatoid arthritis (RA) seen in everyday practice, under the aegis of the French Society for Rheumatology...
  53. ncbi request reprint TNFalpha antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, 147, Bd Baille, 13005 Marseille, France
    Joint Bone Spine 73:547-53. 2006
    ..To develop recommendations for TNFalpha antagonist therapy in patients with spondyloarthropathies...
  54. ncbi request reprint Anti-tumor necrosis factor alpha therapy in fifteen patients with AA amyloidosis secondary to inflammatory arthritides: a followup report of tolerability and efficacy
    Jacques Eric Gottenberg
    Hopital de Bicetre, Paris, France
    Arthritis Rheum 48:2019-24. 2003
    ....
  55. ncbi request reprint Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with rheumatoid arthritis
    Bruno Fautrel
    Pierre and Marie Curie University Paris VI, UFR de Medecine, France
    Joint Bone Spine 74:627-37. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of TNFalpha antagonists for treating patients with rheumatoid arthritis (RA)...
  56. ncbi request reprint Recommendations of the French Society for Rheumatology regarding TNFalpha antagonist therapy in patients with ankylosing spondylitis or psoriatic arthritis: 2007 update
    Thao Pham
    Rheumatology Department, La Conception Teaching Hospital, 147 Boulevard Baille, 13005 Marseille, France
    Joint Bone Spine 74:638-46. 2007
    ..To update French Society for Rheumatology guidelines regarding the use of tumor necrosis factor alpha (TNFalpha) antagonists for treating patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA)...
  57. ncbi request reprint Influence of sex on disease severity in patients with rheumatoid arthritis
    Laure Gossec
    Department of Rheumatology B, Cochin Hospital, AP HP, Rene Descartes University, Paris, France
    J Rheumatol 32:1448-51. 2005
    ..To determine whether patient's sex influences the severity of rheumatoid arthritis (RA) in terms of clinical severity or need for treatments...
  58. ncbi request reprint Structural evaluation in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Laure Gossec
    Rheumatology Department, Cochin Teaching Hospital, Paris, France
    Joint Bone Spine 72:229-34. 2005
    ..To develop French evidence-based recommendations for the structural evaluation of rheumatoid arthritis (RA) in everyday practice...
  59. ncbi request reprint Clinical practice format for choosing a second-line disease modifying anti-rheumatic drug in early rheumatoid arthritis after failure of 6 months' first-line DMARD therapy
    Olivier Meyer
    Department of Rheumatology, AP HP, Bichat Paris 7 University Hospital, CHU Bichat, 46 rue Henri Huchard, 75018 Paris, France
    Joint Bone Spine 74:73-8. 2007
    ..The objective was to develop a clinical practice format for choosing a second-line disease-modifying anti-rheumatic drug (DMARD) after a 6-month course of a first-line DMARD in patients with early RA...
  60. ncbi request reprint Switching between anti-TNFalpha agents: what is the evidence?
    Bernard Combe
    Joint Bone Spine 71:169-71. 2004
  61. ncbi request reprint Cardiovascular risk and rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 73:379-87. 2006
    ..To develop clinical practice guidelines for the evaluation and management of cardiovascular risk in patients with rheumatoid arthritis (RA), using the evidence-based approach and expert opinion...
  62. ncbi request reprint Nonpharmacological treatments in early rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Laure Gossec
    Service de Rhumatologie B, CHU de Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Joint Bone Spine 73:396-402. 2006
    ..To develop clinical practice guidelines for the use of nonpharmacological treatments in patients with early rheumatoid arthritis (RA), using the evidence-based approach and expert opinion...
  63. ncbi request reprint The rheumatoid shoulder: current consensus on diagnosis and treatment
    Thierry Thomas
    Rheumatology Department, St Etienne University Hospital, boulevard Pasteur, 42055 Saint Etienne Cedex 02, France
    Joint Bone Spine 73:139-43. 2006
    ..Stepwise use of local interventions as indicated by imaging findings is recommended. Joint replacement should not be left too late, and surgical procedures on the shoulder should be built into the overall treatment plan...
  64. ncbi request reprint Imaging for the diagnosis and follow-up of ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Stephan Pavy
    service de médecine interne 1, CHU Pitie Salpetriere, Paris, France
    Joint Bone Spine 74:338-45. 2007
    ..To develop recommendations regarding imaging studies for the diagnosis and follow-up of patients with axial forms of ankylosing spondylitis (AS) seen in everyday practice...
  65. ncbi request reprint Use of combination of leflunomide with biological agents in treatment of rheumatoid arthritis
    Joachim R Kalden
    Medizinische Klinik III, Institute for Clinical Immunology, Erlangen, Germany
    J Rheumatol 32:1620-31. 2005
    ....
  66. ncbi request reprint Methotrexate therapy for rheumatoid arthritis: clinical practice guidelines based on published evidence and expert opinion
    Stephan Pavy
    Service de Rhumatologie A, CHU Cochin, 27, rue du Faubourg Saint Jacques, 75014 Paris, France
    Joint Bone Spine 73:388-95. 2006
    ..To develop clinical practice guidelines for the use of methotrexate in rheumatoid arthritis (RA), using the evidence-based approach and expert opinion...
  67. doi request reprint Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
    Maxime Breban
    Hopital Ambroise Pare, Assistance Publique Hopitaux de Paris, Boulogne Billancourt, France
    Arthritis Rheum 58:88-97. 2008
    ..This study was undertaken to compare the efficacy of continuous treatment with infliximab with that of a treatment regimen adapted to symptom recurrence. Methotrexate (MTX) in combination with infliximab was also tested...
  68. ncbi request reprint Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice
    Aleth Perdriger
    Department of Rheumatology, Medical University, Rennes, France
    J Rheumatol 33:865-9. 2006
    ..To investigate the safety of infliximab (INF) combination therapy with leflunomide (LEF) or azathioprine (AZA) in patients with rheumatoid arthritis (RA)...
  69. ncbi request reprint Clinical and laboratory follow-up for treating and monitoring patients with ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Emmanuelle Dernis
    Service de Rhumatologie, CH Le Mans, Le Mans, France
    Joint Bone Spine 74:330-7. 2007
    ..To develop French recommendations about the clinical and laboratory follow-up of patients with axial ankylosing spondylitis (AS) seen in everyday practice...
  70. ncbi request reprint Physical examination and laboratory tests in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Thao Pham
    Service de Rhumatologie, CHU de la Conception, Marseille, France
    Joint Bone Spine 72:222-8. 2005
    ..To develop recommendations for the physical and laboratory-test follow-up of patients with rheumatoid arthritis (RA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed...
  71. ncbi request reprint The 5-yr HAQ-disability is related to the first year's changes in the narrowing, rather than erosion score in patients with recent-onset rheumatoid arthritis
    Jean Francis Maillefert
    Centre Hospitalier Universitaire Dijon, Dijon, France
    Rheumatology (Oxford) 43:79-84. 2004
    ..To evaluate the predictive validity of radiological change on 5-yr disability in rheumatoid arthritis (RA)...
  72. ncbi request reprint Role and modalities of information and education in the management of patients with rheumatoid arthritis: development of recommendations for clinical practice based on published evidence and expert opinion
    Bruno Fautrel
    Service de Rhumatologie, Groupe Hospitalier Pitie Salpetriere, Paris, France
    Joint Bone Spine 72:163-70. 2005
    ..To develop recommendations for the information and education of patients with rheumatoid arthritis (RA) seen in everyday practice, using evidence from the literature, supplemented with expert opinion when needed...
  73. ncbi request reprint Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)
    Xavier Mariette
    Service de Rhumatologie, Hôpital de Bicêtre AP HP, and Université Paris Sud, Le Kremlin Bicetre, France
    Arthritis Rheum 50:1270-6. 2004
    ..Since tumor necrosis factor alpha (TNF alpha) could be a key element in the pathogenesis of primary SS, we conducted a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the effect of infliximab in primary SS...
  74. ncbi request reprint Leflunomide combined with conventional disease-modifying antirheumatic drugs or biologics in patients with rheumatoid arthritis
    Bernard Combe
    Joint Bone Spine 73:587-90. 2006
  75. ncbi request reprint Pharmacotherapy (excluding biotherapies) for ankylosing spondylitis: development of recommendations for clinical practice based on published evidence and expert opinion
    Frédéric Lavie
    Service de Rhumatologie, Hopital de Bicetre, Le Kremlin Bicetre, France
    Joint Bone Spine 74:346-52. 2007
    ..To develop recommendations about pharmacotherapy (excluding biotherapeutic agents) in patients with axial forms of ankylosing spondylitis (AS) seen in everyday clinical practice...